US EditionAstraZeneca And Daiichi Sankyo Secure Early Access Deal For ENHERTU - Canadian Manufacturing
Summary by Canadian Manufacturing
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AstraZeneca And Daiichi Sankyo Secure Early Access Deal For ENHERTU - Canadian Manufacturing
MISSISSAUGA — Canada’s Drug Agency has issued a Time-Limited Reimbursement recommendation for ENHERTU (trastuzumab deruxtecan), marking the first such recommendation for gastric cancer. This applies to adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received a trastuzumab-based regimen. In addition, AstraZeneca, Daiichi Sankyo, and the pa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
